This message was sent to ##Email##
|
|
|
|
|
SCAI
Registration is now open for Interventional Cardiology's Annual Meeting: SCAI 2016.
Taking place May 4-7 in Orlando, Florida, SCAI 2016 will focus on translating science to practice for coronary, congenital, structural and peripheral interventionalists as well as the whole cath lab team. No other meeting beats our objective, evidence-based education designed to improve your interventional practice.
Plus, this year we will have a renewed emphasis on science presented in Orlando. Submit your abstract today!
Not yet a member? Join our professional society and save up to $650!
Register today, and see you in Orlando!
SCAI
The Centers for Medicare and Medicaid Services opened the Physician Compare quality measure preview period Oct. 5. The 30-day preview period provides an opportunity for individuals and group practices to review their 2014 quality measures before they are reported on Physician Compare later this year. You can access the secured measures preview site now through the PQRS portal — Provider Quality Information Portal (PQIP). To learn more about which measures will be publicly reported and how to preview your measures, visit the Physician Compare Initiative page.
If you have any questions about Physician Compare, public reporting or the 2014 quality measure preview period, please contact PhysicianCompare@Westat.com.
SCAI
Society members are being reminded that the SCAI Helping Hearts Lifetime Service Award nomination deadline is Oct. 31. The award recognizes members who have provided outstanding service to SCAI over their lifetime. Award recipients recognized by their peers have demonstrated substantial and consistent service to the Society for over 25 years as SCAI members, having:
- Provided a moral and ethical example for others;
- Striven for excellence in patient care; and
- Dedicated themselves to the highest professional standards.
Learn more.
MassDevice
The Absorb bioabsorbable stent made by Abbott met its primary endpoint in a U.S. clinical trial that will be used to back a bid for Food and Drug Administration approval, researchers said at the annual Transcatheter Cardiovascular Therapeutics conference in San Francisco. One-year data from the Absorb III trial of 2,008 patients showed that the Absorb device was noninferior to Abbott's flagship Xience drug-eluting stent.
READ MORE
MedPage Today
 News reports claiming an increased stroke risk for patients with bioprosthetic aortic valves overstated the risk and triggered a near panic among patients implanted with the valves, according to Raj Makkar, MD, lead author of the study, which was published in The New England Journal of Medicine.
Makkar, who spoke as part of a transcatheter aortic valve replacement panel at the Transcatheter Cardiovascular Therapeutics meeting, was especially critical of national news reports in the Wall Street Journal and by The Associated Press, which ignored the paper's cautious language describing "possible subclinical leaflet thrombosis" and trumpeted stroke risk.
READ MORE
 |
|
GLIDESHEATH SLENDER® 5Fr and 7Fr!
The only family of unique thin-wall sheaths, offering radial access to more patients.
• Increase Your Radial Access Options
• Optimize Procedural Outcomes
• Preserve Arterial Function
*GLIDESHEATH SLENDER® is also available in 6Fr.
©2015 Terumo Medical Corporation. All rights reserved.
All brand names are trademarks or registered trademarks of Terumo. TIS-694-06012015
|
|
TCTMD
Elderly patients undergoing PCI are increasingly characterized by a higher comorbidity burden and are more likely to present with acute MI, according to results of a large U.S. registry study presented at TCT 2015. In-hospital and 30-day mortality rates are also on the rise, with the largest increase seen in patients undergoing elective PCI.
READ MORE
Healio
The LIBERTY-360 and ENDOMAX trials have the potential to provide novel, much-needed data on the use of available endovascular tools for treating outflow disease, particularly critical limb ischemia, according to a presentation at the TCT Scientific Symposium. "The rise in revascularization and endovascular therapy began, in the U.S. at least, around 2001 and 2002. We really saw an exponential increase, and those trends continue today," Herbert D. Aronow, MD, MPH, FSCAI, director of interventional cardiology and cardiac catheterization labs at the Rhode Island & the Miriam Hospitals, said during a presentation.
READ MORE
MedPage Today
The second-generation DREAMS stent, made of a drug-eluting bioresorbable magnesium alloy scaffold, appeared promising for safety and efficacy, researchers reported in the first-in-man trial.
Implantation was "feasible, with favorable safety and performance outcomes at six months," , of Lukaskrankenhaus in Neuss, Germany, and colleagues wrote online in The Lancet in conjunction with presentation at the Transcatheter Cardiovascular Therapeutics meeting.
READ MORE
Healio
The development of an integrated, multispecialty team must be a concept "embedded" in the approach to care for patients with mitral valve disease, according to a presentation on the creation of a mitral valve heart team at annual TCT Scientific Symposium. "Fundamentally, we believe that cardiology and surgery [have] to get together," said David L. Brown, MD, FACC, FACP, FSCAI, founder of The Heart Hospital Baylor Plano and president and chairman of the medical staff.
READ MORE
Cardiovascular Business
A meta-analysis of five randomized controlled trials found that performing endovascular therapy with stent retrievers was safe and effective in managing acute ischemic stroke and led to a significant improvement in functional clinical outcomes compared with standard therapy. There was no difference in the rates of symptomatic intracranial hemorrhage in patients receiving stent retrievers or standard therapy, while there appeared to be a trend towards overall decreased 90-day mortality in the stent retriever group.
READ MORE
 |
|
Whether you are a healthcare professional, a patient or simply someone looking to know more about the complete solutions offered by Cordis, let us show you how our distinctive approach to working in partnership with you results in innovative interventional products and services to help support sustained patient outcomes.
|
|
MedPage Today
Transradial access was as good as going through the groin for outcomes in ad hoc percutaneous coronary intervention reflecting real-world practice, and modestly reduced bleeding, a randomized trial from China showed.
The primary endpoint of major adverse cardiac or cerebrovascular event (MACCE)-free rate at 12 months came out 95.8 percent for radial compared to 95.5 percent for femoral access, which easily met the non-inferiority criterion, Shigeru Saito, MD, of Shonan Kamakura General Hospital in Kanagawa, Japan, and colleagues found.
READ MORE
| Date |
Event |
Location |
| Oct. 29-31 |
SCAI at Great Wall International Congress of Cardiology |
Beijing, CHINA
|
| Nov. 13-15 |
SCAI Fellows Course at AICT 2015 |
Dhaka, BANGLADESH
|
| Dec. 6-9 |
SCAI 2015 Fall Fellows Courses |
Las Vegas
|
| Feb. 25 |
SCAI Session at CardioEgypt 2016 |
Cairo, EGYPT
|
| May 4-7 |
SCAI 2016 Scientific Sessions |
Orlando, FL
|
For a complete list of job postings, click here.
To post your resume, click here.
|
Missed last week's issue? See which articles your colleagues read most.
|
|
Don't be left behind. Click here to see what else you missed.
|
|
|
|
|
|
|
|
|
|
7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063
|
